Part I: Chemotherapy for epithelial ovarian cancer–treatment at first diagnosis
- 1 September 2002
- journal article
- review article
- Published by Elsevier in The Lancet Oncology
- Vol. 3 (9) , 529-536
- https://doi.org/10.1016/s1470-2045(02)00846-x
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinomaThe Lancet, 2001
- Cancer Statistics, 2001CA: A Cancer Journal for Clinicians, 2001
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI Journal of the National Cancer Institute, 2000
- Phase II trials of docetaxel (taxotere®) in advanced ovarian cancer—an updated overviewEuropean Journal Of Cancer, 1997
- DNA Index Reflects the Biological Behavior of Ovarian Carcinoma Stage I–IIaGynecologic Oncology, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- The importance of dose and schedule in cancer chemotherapyAnti-Cancer Drugs, 1995
- Analysis of prognostic factors in stage I epithelial ovarian carcinoma: Importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapseAmerican Journal of Obstetrics and Gynecology, 1993
- A Prospective Randomized Comparison of 6 and 12 Cycles of Cyclophosphamide, Adriamycin, and Cisplatin in Advanced Epithelial Ovarian Cancer: A Danish Ovarian Study Group Trial (DACOVA)Gynecologic Oncology, 1993
- High dose cisplatin and high dose carboplatin in refractory ovarian cancerCancer Treatment Reviews, 1985